International biopharmaceutical company GNI has opened an institute in Fukuoka, Japan, that will integrate the gene network studies being conducted at GNI's Kurume Research Laboratory with the GNI research group at Kyushu University in Japan. It will also support their activities with new in-house super-computers.
GNI exploits gene regulatory networks and systems pharmacology to develop human therapeutics that are more effective and have fewer side-effects than drugs developed with other genomic methods.
Located at the Fukuoka System Large Scale Integration (LSI) Multipurpose Development Center, GNI's new institute will use supercomputers and vast quantities of GNI proprietary gene regulation data from human cells to analyse the regulatory networks across the human genome that determine responses to drugs and drug candidates.
GNI's chairman, Dr Christopher Savoie, said: "We are delighted to launch the GNI Systems Pharmacology Research Institute, which will operate at the heart of the collaboration between GNI's laboratories at the University of Cambridge in the UK and its research departments within Shanghai Genomics in China to further advance GNI's global drug development capabilities."